Which Second-Line drug works best for axial spondyloarthritis? a trial aims to find out
NCT ID NCT07770646
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This trial tests two different types of drugs—an IL-17 inhibitor (secukinumab) and a JAK inhibitor (upadacitinib)—in people with axial spondyloarthritis who have not improved with a TNF inhibitor. The goal is to see which approach is more effective at reducing disease activity over 16 weeks, and to check if a larger study is feasible. Participants will receive either weekly injections of secukinumab or daily oral upadacitinib, with regular assessments of symptoms and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Secukinumab (IL-17 inhibitor) and upadacitinib (JAK inhibitor)
- What this could lead to
- If successful, this trial could guide doctors on which second-line treatment works best for axial spondyloarthritis when the first biologic fails, improving symptom control and quality of life.
- What could go wrong
- This is a small pilot study, so results may not be definitive. Both drugs carry risks like infections, and the trial may not show a clear winner.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS (AXSPA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas health Science Center at Houston
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new criteria better spot a spine disease that mimics back pain?
- Digital diary aims to decode painful flares in spine condition
- Could a common arthritis drug tame recurring eye inflammation?
- Blood sample study explores new target for inflammatory arthritis
- Breathing new life: exercise program shows promise for stiff spine patients
- New pill aims to tame back inflammation in axial spondyloarthritis